Analysts Set Simulations Plus, Inc. (NASDAQ:SLP) PT at $49.40

Shares of Simulations Plus, Inc. (NASDAQ:SLP) have been assigned an average rating of “Buy” from the seven brokerages that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $49.40.

SLP has been the subject of a number of recent research reports. BTIG Research dropped their price objective on shares of Simulations Plus from $60.00 to $50.00 and set a “buy” rating for the company in a research note on Thursday, October 24th. KeyCorp boosted their price objective on Simulations Plus from $35.00 to $37.00 and gave the stock an “overweight” rating in a research note on Friday, January 24th. Stephens began coverage on Simulations Plus in a research report on Friday, November 15th. They set an “overweight” rating and a $39.00 price objective on the stock. StockNews.com cut Simulations Plus from a “hold” rating to a “sell” rating in a report on Monday, November 4th. Finally, William Blair restated an “outperform” rating on shares of Simulations Plus in a report on Wednesday, January 8th.

Insider Transactions at Simulations Plus

In related news, Director Walter S. Woltosz sold 20,000 shares of the firm’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $33.91, for a total value of $678,200.00. Following the transaction, the director now owns 3,402,584 shares of the company’s stock, valued at $115,381,623.44. This trade represents a 0.58 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 19.40% of the company’s stock.

Hedge Funds Weigh In On Simulations Plus

A number of institutional investors have recently modified their holdings of the stock. Conestoga Capital Advisors LLC boosted its holdings in shares of Simulations Plus by 15.0% in the fourth quarter. Conestoga Capital Advisors LLC now owns 2,226,262 shares of the technology company’s stock valued at $62,090,000 after purchasing an additional 290,414 shares during the period. State Street Corp lifted its holdings in shares of Simulations Plus by 4.7% in the 3rd quarter. State Street Corp now owns 640,303 shares of the technology company’s stock worth $20,503,000 after buying an additional 28,953 shares during the period. Geode Capital Management LLC grew its position in shares of Simulations Plus by 4.4% during the 3rd quarter. Geode Capital Management LLC now owns 448,618 shares of the technology company’s stock worth $14,367,000 after buying an additional 18,924 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Simulations Plus by 10.1% during the second quarter. Dimensional Fund Advisors LP now owns 414,005 shares of the technology company’s stock valued at $20,128,000 after buying an additional 37,992 shares during the period. Finally, Tributary Capital Management LLC raised its holdings in shares of Simulations Plus by 21.7% in the fourth quarter. Tributary Capital Management LLC now owns 396,093 shares of the technology company’s stock valued at $11,047,000 after acquiring an additional 70,526 shares in the last quarter. 78.08% of the stock is owned by hedge funds and other institutional investors.

Simulations Plus Stock Performance

SLP stock opened at $36.28 on Friday. The firm has a fifty day moving average price of $30.72 and a 200 day moving average price of $32.47. Simulations Plus has a fifty-two week low of $24.00 and a fifty-two week high of $51.22. The firm has a market cap of $728.87 million, a PE ratio of 90.70 and a beta of 0.82.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.